Counterparties stepping up before the numbers do: escalating committed demand the reported results don't yet show
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes counterparties stepping up their commitment beyond prior levels, and that reported results don't yet reflect that step-up because it's only beginning. Let's examine the transcript. Key points: - Perkin Elmer partnership: "co-marketing agreement recently announced is the first step in building a strong ongoing relationship" and "we estimate 2019 revenues between several hundreds to several million dollars resulting from the market penetration of ICP within current and future Perkin Elmer and Precipio customers" - this is a new partnership, but is it a step-up from prior level? It's a new relationship, not an escalation of existing business. Also, it's future revenue estimate, not yet committed orders. Management says "first step" and "potential" - not yet a committed escalation. - Pathology services: "revenues from pathology services growing close to 50% from the previous quarter" and "we expect a continued rapid growth" - that's growth, but is it a step-up beyond prior level? They mention "substantial pipeline of new customers and strong conversion rates" - but that's pipeline, not committed. They also say "revenues from pathology services alone exceeding $1 million per quarter by the middle of 2019" - that's a forecast, not current commitment. - HemeScreen: "Since the launch of the test in our lab, only two weeks ago, we've already received numerous orders -- we've already run numerous orders received from physicians." That's actual orders, but is it a step-up? It's a new test, so it's new business, but it's not an escalation of existing counterparties. Also, they say "we believe that given the market volume and revenue numbers of the current inferior test, that HemeScreen can generate revenues in excess of $1 million in 2019" - that's a projection, not yet realized. - IV-Cell: "commercialization process proceeded in parallel" and "we believe we're making great strides" - no specific committed orders. - The overall message: They have growth, but the question asks specifically about counterparties stepping up their commitment beyond prior level, and that reported results don't yet reflect that step-up because it's only beginning.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
KOP · Q2 2018 → YESThe question is: Does management describe that counterparties (customers etc.) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that reported results do not yet meaningfully reflect...**NO** The transcript does not describe any counterparties (customers, clients, partners, etc.) currently stepping up their commitment to a distinctly higher level of engagement beyond prior patterns in a way that is already occurring or committed now, with the reported results lagging because most of the benefit is still ahead. The closest item is the major box store converting its ground-contact treated wood program to Koppers’ patented MicroPro technology, planned for late fall with “little effect on the balance of 2018” and a “nice boost heading into 2019.
SCPH · Q3 2023 → YESThe question is: Does management describe that counterparties who pay the company are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully ...YES The transcript shows management describing a clear escalation in payer commitments: a new unrestricted-access agreement with the largest closed IDN (over 8 million lives, fixed copay) and preferred formulary status with a major government retiree payer (adding 1.1 million lives). They explicitly note that direct IDN purchases were not meaningful in Q3 but will be “a meaningful part of our business” moving forward, especially in 2024, and that the new payer decisions “could positively impact FUROSCIX co-pays as early as the fourth quarter.
GFS · Q3 2021 → YESThe question is: Does management describe that counterparties (customers) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully reflect ...**YES** Management describes counterparties (customers) stepping up their commitment through new and expanded long-term agreements (LTAs) and prepayments/access fees, which have grown since the roadshow (from ~$2.5B to north of $3B, with additional $500M+ added post-roadshow) and now exceed $20B in forward revenues. This is framed as real escalation in committed business, with customers signing more agreements and prepaying for future capacity. The reported Q3 results ($1.7B revenue, $0.07 adjusted EPS) and Q4 guidance ($1.